Karyopharm Therapeutics Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 78/100
What the filing says
Karyopharm (market cap ~$37M) reported Q2 2026 revenue of $33.4M ($30.8M product, $2.6M other) versus $37.9M YoY; reaffirmed FY2026 guidance of $130–150M total revenue ($115–130M product). Key catalyst: planned August 2026 sNDA submission for selinexor+ruxolitinib in myelofibrosis under Accelerated Approval, supported by Phase 3 SENTRY data. Critical liquidity crisis: cash of $65.4M as of June 30, 2026 covers operations only into September 2026; $15.8M debt payment due September 10, 2026 would breach $10M minimum liquidity covenant, triggering default. Company actively seeking financing/strategic alternatives. Endometrial cancer Phase 3 failed primary endpoint (median PFS 12.75 vs 7.43 months, p=0.0791, one-sided).
Why this rating
Myelofibrosis regulatory catalyst highly positive; failed endometrial trial negative. Liquidity crisis dominates—$15.8M payment September 2026 on ~$37M market cap is existential. Strategic necessity outweighs clinical upside.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.